Related Experiment Video
Updated: Jun 4, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor
Adele L McCormick1, Chris M Parry, Anne Crombe
1Centre of Virology, Royal Free and University College London Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom. a.mccormick@medsch.ucl.ac.uk
Abstract:
We investigated the effect of N348I alone and with M184V on nonnucleoside reverse transcriptase inhibitor (NNRTI) drug susceptibility and replicative capacity in B and non-B HIV-1 isolates. N348I reduced the susceptibility to all NNRTI drugs across subtypes. The replication capacity of all viruses in a variety of cell lines was impaired by N348I. Interestingly, the N348I and M184V double mutation compensated for the reduced NNRTI drug susceptibility observed in the N348I single mutant and marginally improved viral replicative capacity.
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Antiviral Nucleoside Inhibitors
Viral Mutations

